文献速递性腺与生殖内分泌垂体与肾上腺疾病

抑制素B和抗苗勒管激素用于诊断1岁以下男孩低促性腺激素性性腺功能减退症:病例对照研究

Inhibin B and AMH for Diagnosis of Hypogonadotropic Hypogonadism in Boys Under 1 Year of Age: A Case-control Study.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

这项法国7家大学医院的多中心病例对照研究纳入138例0–12月龄男孩(58例孤立性先天性低促性腺激素性性腺功能减退症(iCHH),其中28例有阳性分子诊断;32例联合垂体激素缺乏症(CPHD);48例特发性对照),比较抑制素B(INHB)、抗苗勒管激素(AMH)、睾酮(T)、LH和FSH的鉴别诊断价值。结果发现,在小青春期之外,INHB和AMH的鉴别性能良好(ROC曲线下面积≥0.95),作者认为INHB和/或AMH可用于诊断1岁以下男孩的CHH。

要点

  • INHB和/或AMH在四个年龄段区分CHH与对照的ROC曲线下面积均≥0.95。
  • 1–4天龄INHB在150 pg/mL时敏感度/特异度100%/75%,在85 pg/mL时89%/100%。
  • 180天龄后INHB在100 pg/mL时敏感度/特异度100%/100%;AMH在600 pmol/L时100%/92%,在370 pmol/L时75%/100%。

核心结论

  • 抑制素B和/或AMH可用于诊断1岁以下男孩的先天性低促性腺激素性性腺功能减退症(CHH)。

研究设计与样本

  • 法国7家大学医院的多中心病例对照研究,纳入138例0–12月龄男孩,其中孤立性CHH(iCHH)58例(含28例阳性分子诊断)、联合垂体激素缺乏症(CPHD)32例、特发性对照48例。
  • 研究分析四个年龄段:1–4天、15–65天(小青春期早期,对应睾酮峰值)、66–179天(小青春期晚期)、180–365天(小青春期后)。

主要发现

  • 小青春期之外,1–4天龄鉴别最佳激素为INHB:150 pg/mL时敏感度/特异度100%/75%,85 pg/mL时89%/100%。
  • 180天龄后INHB在100 pg/mL时敏感度/特异度100%/100%;AMH在600 pmol/L时100%/92%,在370 pmol/L时75%/100%。
  • INHB和/或AMH在全部4个年龄段的鉴别性能良好(ROC曲线下面积≥0.95)。

关键数值与推荐

  • 1–4天龄INHB 150 pg/mL:敏感度100%、特异度75%。
  • 1–4天龄INHB 85 pg/mL:敏感度89%、特异度100%。
  • 180天龄后INHB 100 pg/mL:敏感度100%、特异度100%。
  • 180天龄后AMH 600 pmol/L:敏感度100%、特异度92%;AMH 370 pmol/L:敏感度75%、特异度100%。

临床怎么用

  • 作者认为抑制素B和/或AMH可用于诊断1岁以下男孩的CHH。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Congenital hypogonadotropic hypogonadism (CHH) in infant boys is a rare disorder that can manifest as micropenis and/or cryptorchidism. Mini-puberty is considered a window of opportunity for CHH diagnosis and treatment. The lack of testosterone (T) elevation during this period is the gold standard for CHH diagnosis, but hormonal evaluation is not always available at this time. OBJECTIVES: The aim was to compare inhibin B (INHB), anti-Müllerian hormone (AMH), T, LH, and FSH between infant boys (1 to 365 days) with micropenis and/or cryptorchidism due to isolated CHH (iCHH), CHH as part of combined pituitary hormone deficiency (CPHD), or of idiopathic origin (controls) and to determine discriminating cutoffs for CHH diagnosis based on sensitivity (Se) and specificity (Sp). METHODS: This multicenter study from 7 University Hospitals in France included 138 boys aged 0 to 12 months (58 with iCHH, including 28 with a positive molecular diagnosis, 32 with CPHD, and 48 controls). Four periods of interest were studied: between 1 to 4 days, 15 to 65 days (early mini-puberty, corresponding to the T peak), 66 to 179 days (late mini-puberty), and 180 to 365 days (post mini-puberty). RESULTS: Out of mini-puberty, the best-discriminating hormones were INHB between 1 to 4 days (Se/Sp 100%/75% at 150 pg/mL and 89%/100% at 85 pg/mL) and INHB and AMH after 180 days (INHB: Se/Sp 100%/100% at 100 pg/mL; AMH: Se/Sp 100%/92% at 600 pmol/L, and 75%/100% at 370 pmol/L). INHB and/or AMH discriminating performances were good (area under the receiver operating characteristic curve ≥ 0.95) across all 4 periods. CONCLUSION: Inhibin B and/or AMH can be used to diagnose CHH in boys < 1 year of age.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Gueguen T, Martinerie L, Castets S, et al. Inhibin B and AMH for Diagnosis of Hypogonadotropic Hypogonadism in Boys Under 1 Year of Age: A Case-control Study. J Clin Endocrinol Metab. 2025. PMID: 40193582. doi:10.1210/clinem/dgaf219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。